Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2005
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
Ashraf Z Badros, Olga Goloubeva, Aaron P Rapoport, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1996
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer
B L Gause, M Sznol, W C Kopp, et al.
International Journal of Molecular Sciences
|
July 9, 2022
11β-Hydroxysteroid Dehydrogenase Type 1 within Osteoclasts Mediates the Bone Protective Properties of Therapeutic Corticosteroids in Chronic Inflammation
Chloe G Fenton, Ana Crastin, Claire S Martin, et al.
Arthritis Research & Therapy
|
August 3, 2019
Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis
C G Fenton, J M Webster, C S Martin, et al.
Nature Communications
|
June 30, 2023
Author Correction: Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation
Alicia Villatoro, Vincent Cuminetti, Aurora Bernal, et al.
Nature Communications
|
January 3, 2023
Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation
Alicia Villatoro, Vincent Cuminetti, Aurora Bernal, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
July 1, 1996
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients
B D Curti, A C Ochoa, W J Urba, et al.
Journal of the National Cancer Institute
|
January 3, 1996
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma
J E Janik, L L Miller, D L Longo, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
September 1, 1996
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma
R G Fenton, R G Steis, K Madara, et al.
Bone Marrow Transplantation
|
February 10, 2004
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
G L Phillips, B R Meisenberg, D E Reece, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2005
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
Ashraf Z Badros, Olga Goloubeva, Aaron P Rapoport, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1996
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer
B L Gause, M Sznol, W C Kopp, et al.
International Journal of Molecular Sciences
|
July 9, 2022
11β-Hydroxysteroid Dehydrogenase Type 1 within Osteoclasts Mediates the Bone Protective Properties of Therapeutic Corticosteroids in Chronic Inflammation
Chloe G Fenton, Ana Crastin, Claire S Martin, et al.
Arthritis Research & Therapy
|
August 3, 2019
Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis
C G Fenton, J M Webster, C S Martin, et al.
Nature Communications
|
June 30, 2023
Author Correction: Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation
Alicia Villatoro, Vincent Cuminetti, Aurora Bernal, et al.
Nature Communications
|
January 3, 2023
Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation
Alicia Villatoro, Vincent Cuminetti, Aurora Bernal, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
July 1, 1996
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients
B D Curti, A C Ochoa, W J Urba, et al.
Journal of the National Cancer Institute
|
January 3, 1996
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma
J E Janik, L L Miller, D L Longo, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
September 1, 1996
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma
R G Fenton, R G Steis, K Madara, et al.
Bone Marrow Transplantation
|
February 10, 2004
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
G L Phillips, B R Meisenberg, D E Reece, et al.
Page
of 11